Oncology Partnering Deals

Übersicht:

M&A-Trends in der Pharma- und Biotech-Branche: Analyse eines Geschäftsmodells
http://www.innovations-report.de/html/berichte/studien/m_a_t…


Liste der aktivsten Dealmaker der letzen Jahre:

Pfizer, Roche, Novartis AG, Sanofi-Aventis, Schering Plough, Eli Lilly, Amgen, GlaxoSmithKline, Johnson & Johnson, Abbott, Astellas, AstraZeneca, Bayer Schering Pharma AG, Bristol-Myers Squibb, Merck & Co, Merck – Serono KgaA, Wyeth, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Takeda, Teva, Eisai, Otsuka


Weniger aktive Unternehmen:

Actavis, Akzo Nobel, Alcon Labs, Allergan, Baxter International, Biogen Idec, Cephalon, Chugai, CSL, Dainippon Sumitomo, Forest Laboratories, Genzyme, Gilead Sciences, King, Lundbeck, Menarini, Mitsubishi, Nycomed Pharma, Procter & Gamble, Shionogi Seiyaku, Shire, Solvay, Tanabe Seiyaku, TAP Pharmaceuticals, UCB,Watson

 

GSK - Genmab
December 2006 - Phase III - $2,100m http://www.gsk.com/media/pressreleases/2006/2006_12_19_GSK94…

GlaxoSmithKline and Genmab announced a worldwide agreement to co-develop and commercialize HuMax-CD20 (ofatumumab).

Under the terms of the agreement, Genmab will receive a license fee of DKK 582 million (approximately $102 million), and GSK will invest DKK 2,033 million (approximately $357 million) to purchase, 4,471,202 ordinary shares of Genmab. The total potential value of this agreement, in the event of full commercial success, in cancer and various autoimmune and inflammatory diseases, could exceed DKK 12.0 billion (approximately $2.1 billion), including the initial license fee and equity purchase, milestone payments, totaling DKK 9.0 billion (approximately $ 1.6 billion) and expected development, commercial manufacturing and commercialization costs.

In addition, Genmab will be entitled to receive tiered double digit royalties on global sales of HuMax-CD20.

GSK will receive an exclusive worldwide license to HuMax-CD20 as well as any other antibodies with affinity for the CD20 antigen which Genmab may develop. GSK will also have an exclusive option to a CD20 UniBody to be developed in collaboration with Genmab. GSK and Genmab will co-develop HuMax-CD20. Genmab will be responsible for development costs until 2008, including costs of the two ongoing late stage oncology studies after which development costs will be shared equally between GSK and Genmab. GSK will be solely responsible for the manufacturing and commercialization of HuMax-CD20.

Genmab will have an option to co-promote HuMax-CD20 in a targeted oncology setting in the US and in the Nordic region. Should this be undertaken, Genmab will also have the option co-promote Bexxar and Arranon in the US and Atriance in the relevant countries of the Nordic region.

Novartis - Antisoma
April 2007 - Phase II - $890m http://www.antisoma.com/asm/media/press/pr2007/2007-04-19a/

Antisoma has signed an exclusive global licensing agreement with Novartis for its vascular disrupting agent AS1404 (DMXAA).

Antisoma will receive near-term payments of USD 100 million. $75 million will be paid immediately and a further $25 million when AS1404 enters a phase III trial in lung cancer.

Antisoma will be eligible for total upfront, development, regulatory and sales-related milestone payments of up to $890 million, contingent upon successful development and marketing of AS1404 in multiple indications, launch of back-up products in multiple indications, and achievement of sales milestones. Furthermore, if AS1404 is approved and commercialised, Antisoma will receive royalties on AS1404 sales and will have an option to co-commercialise AS1404 in the United States.

Novartis will fund and conduct all future development of AS1404, and will also fund the outstanding costs of the phase II trials currently being completed by Antisoma. The agreement also includes the potential for Novartis to fund certain of Antisoma’s commercialisation costs.

BMS - Adnexus
February 2007 - Discovery - $1,290m http://www.goodwinprocter.com/NewsEvents/News/Adnexus%20Ther…

Bristol-Myers Squibb and Adnexus Therapeutics announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.

Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus, consisting of upfront and guaranteed research payments. Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments

Sanofi-Aventis - Oxford Biomedica
March 2007 - - Phase II - $690m http://www.bionity.com/news/e/63209/

Oxford BioMedica and sanofi-aventis have entered into an exclusive global licensing agreement to develop and commercialise TroVax for the treatment and prevention of cancers.

Sanofi-aventis will pay Oxford BioMedica up to €518 million (~US$690 million) if all development and registration targets are met for certain defined indications. Additional payments will be made if regulatory milestones are achieved in other cancer types.

Oxford BioMedica will receive an initial payment of €29 million (~US$39 million) and further near-term payments of €19 million (~US$25 million) as milestones linked to the ongoing Phase III TRIST study in renal cancer.

Oxford BioMedica is also entitled to escalating royalties on global sales of TroVax and to further undisclosed commercial milestones when net sales of TroVax reach certain levels.

Oxford BioMedica has an option to develop TroVax for other cancer types in exchange for enhanced financial returns, and sanofi-aventis will keep all commercial rights.

Oxford BioMedica will supply TroVax to sanofi-aventis on commercial terms.

Oxford BioMedica and sanofi-aventis will co-fund the ongoing Phase III TRIST study of TroVax in renal cancer.
Sanofi-aventis will fund all future research, development, regulatory and commercialisation activities, including the immediate implementation of a development plan for TroVax in metastatic colorectal cancer.

Sanofi-aventis will be responsible for the global commercialisation of TroVax and will book the sales worldwide. Oxford BioMedica retains an option to participate in the promotion of TroVax in the United States and the European Union.
 

Merck & Co - ARIAD
July 2007 - Phase II - $1,130m http://www.medicalnewstoday.com/articles/76774.php

ARIAD Pharmaceuticals and Merck & Co have entered into a global collaboration to jointly develop and commercialize AP23573, ARIAD's novel mTOR inhibitor, for use in cancer.

The agreement provides for an initial payment of $75 million to ARIAD, up to $452 million more in milestone payments to ARIAD based on the successful development of AP23573 in multiple cancer indications (including $13.5 million for the initiation of the Phase III clinical trial in metastatic sarcomas and $114.5 million for the initiation of other Phase II and Phase III clinical trials), up to $200 million more based on achievement of significant sales thresholds, at least $200 million in estimated contributions by Merck to global development, up to $200 million in interest-bearing repayable development-cost advances from Merck to cover a portion of ARIAD's share of global-development costs (after ARIAD has paid $150 million in global development costs), and potential commercial returns from profit sharing in the U.S. or royalties paid by Merck outside the U.S

GSK - Synta
October 2007 - Phase III -: $1,100m http://findarticles.com/p/articles/mi_m0EIN/is_2007_Oct_10/a…

GlaxoSmithKline and Synta Pharmaceuticals announced the execution of a global collaboration agreement for the joint development and commercialization of STA-4783, a first-in-class, small-molecule, oxidative stress inducer that is entering Phase 3 clinical development for the treatment of metastatic melanoma.

Under the terms of the agreement, the companies will share responsibility for development and commercialization of STA-4783 in the U.S. and GSK will have exclusive responsibility for development and commercialization of STA-4783 outside the U.S.

Synta will receive an upfront cash payment of $80 million. Synta will also be eligible to receive potential milestone payments of up to $135 million for events leading to approval of STA-4783 in metastatic melanoma, further development and regulatory milestones of up to $450 million across various indications and up to $300 million in potential commercial milestone payments based on achieving certain net sales thresholds. Synta will continue to fund all development for metastatic melanoma in the U.S. and the companies will share responsibility and costs for development of STA-4783 in other indications.

Synta and GSK will jointly commercialize STA-4783 in the U.S. with Synta receiving a tiered profit share based on levels of annual net sales. The parties will share development costs outside of the U.S. and Synta will receive double-digit tiered royalties on net sales. In addition, GSK may, subject to Synta's agreement, purchase, up to $45 million of Synta's common stock upon the future achievement of specified development and regulatory milestones.

Celgene - Array
September 2007 - Cancer, Anti-inflammatory - Discovery - $1,050m http://www.fiercebiotech.com/press-releases/press-release-ar…

Under the agreement, Celgene will make an upfront payment of $40 million to Array, and, in return, Array will grant Celgene an option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets.

Array will be responsible for all discovery and clinical development through Phase 1 or Phase 2a. At that time, Celgene will have the option to select drugs resulting from up to two of these four therapeutic programs and will receive exclusive worldwide rights to those drugs, except for Array's limited co-promotional rights in the U.S.

Additionally, Array is entitled to receive, for each drug, potential milestone payments of approximately $200 million, if certain discovery, development and regulatory milestones are achieved and $300 million if certain commercial milestones are achieved, as well as royalties on net sales. Array will retain all rights to the other programs.